# Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects

> **NCT01624714** · PHASE1 · UNKNOWN · sponsor: **Samuel Forrester Hunter, MD, PhD** · enrollment: 60 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Alemtuzumab
- **DRUG:** Alemtuzumab immunotherapy

## Key facts

- **NCT ID:** NCT01624714
- **Lead sponsor:** Samuel Forrester Hunter, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-09
- **Primary completion:** 2017-04
- **Final completion:** 2017-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2014-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01624714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01624714, "Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01624714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*